AR and neoplasm: Notwithstanding these advancements, some patients experience resistance to existing androgen receptor-targeting therapies,9 underscoring the need for novel agents that can further enhance clinical outcomes, especially for high-volume cases where the tumor burden is substantial and aggressive.